News

Financial self-efficacy and having at least 1 relapse were identified as independent predictors of financial toxicity among patients with multiple sclerosis.

The chief medical officer at Cure SMA detailed the importance of having options for patients and how certain administration routes and schedules offer more personalized approaches, particularly for adult patients with SMA.

Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, shares details from her study on the psychosocial impact on physicians and her first-hand experience.

The investigator at the Healey & AMG Center for ALS at Massachusetts General Hospital spoke to the CENTAUR open-label extension and AMX0035’s development.

The Project ALS-funded oral MAP4 kinase inhibitor has been described in the literature as an exceptionally potent, metabolically stable, and blood-brain barrier-penetrant compound.

Researchers noted that the findings are encouraging for the use of real-world data and natural history data to augment, or possibly replace, placebo controls in DMD trials.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic highlighted the most pressing needs within the Alzheimer disease community.

Treating patients with super-refractory status epilepticus with ketamine showed no effect on intracranial pressure, cerebral blood flow, and cerebral perfusion pressure.

The chief scientific officer at the Parkinson’s Foundation shares his perspective on the current state of Parkinson research and development amid the challenges of the pandemic.

The director of the Sagol Center for Hyperbaric Medicine and Research at Yitzhak Shamir Medical Center offers takeaways on hyperbaric oxygen therapy.

Among individuals at high risk for recurrent ICH, the use of selective serotonin reuptake inhibitors was associated with a greater increase in repeated hemorrhagic stroke.

The investigator at the Healey & AMG Center for ALS detailed the combination of AMX0035 and other agents and how ALSFRS-R scores translate to daily life.

Researchers from Mayo Clinic reported characteristics of 55 patients with a newly defined form of Alzheimer disease with unusual or atypical symptoms.

Neurology News Network for the week ending September 5, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 4, 2020.

Multidisciplinary teams who had the pocket card available had shorter times to rescue therapy initiation and similar rates of adequate dosing.

Despite previous literature documenting cardiovascular disease comorbidity in patients with narcolepsy, pitolisant treatment did not demonstrate any cardiac safety signals.

The pediatric neurologist at Hurley Medical Center of the University of Michigan Hospitals-Michigan Medicine, detailed the challenges those with epilepsy face when transitioning to adult care.

The investigator at the Healey & AMG Center for ALS spoke to the newly released findings of the phase 2/3 trial of the investigational combination ALS agent AMX0035.

The researchers noted that future studies should examine the cost-effectiveness of CT compared with MRI as the best initial imaging modality for mechanical thrombectomy.

Findings suggest that compared with isolated cases, both earlier age at initial episode and a higher prevalence of personal and family history of migraine are linked to TGA recurrence.

The chief research officer and epilepsy specialist at Cleveland Clinic detailed the reasons why epilepsy surgery is not utilized as often as it should, and her efforts to raise awareness.